STRUCTURAL BUY24 Apr 2026 09:11
AI or Not
Clinically validated platform priced as unproven concept — the discount to intrinsic value is structural, not speculative
There is an important distinction between a speculative investment — where you are betting that an unproven concept might work — and an undervalued investment, where you are buying a proven asset at a price that does not reflect what has already been demonstrated. Avacta sits firmly in the second category. The pre|CISION® delivery mechanism has been validated in 63 human patients producing a 100:1 tumour-to-plasma ratio. The safety profile has been confirmed clinically — no maximum tolerated dose at 4× conventional doxorubicin dosing, with the FDA removing the lifetime cap entirely. The payloads are established cytotoxics with decades of data. And as of April 21 2026, AVA6103 has demonstrated activity even in very low FAP tumours, formally expanding the addressable population beyond the already-large FAP-high segment.
This is not a bet on whether the science works. The science works. This is a bet on whether the market re-rates a proven platform from its current ~£349M valuation toward the $1–5bn range that comparable validated drug conjugate platforms command. The risk is financial — dilution, partnership timing, cash runway — not scientific. And financial risk at this stage is considerably more manageable than the binary clinical risk that "speculative" implies. The 10-indication addressable market, the compounding de-risk curve across successive programmes, the Science Day on May 6, and the H2 2026 AVA6103 clinical data all represent catalysts that could close the gap between current price and intrinsic value. At ~77p versus analyst targets of 81–99p and a base-case rNPV of 110–220p, the current price represents an anomalous discount to a platform whose core scientific proposition is no longer in question.
Sign In
Follow the stocks
